DYRK1B and cancer: Thus, an increase in cisplatin toxicity selectively in cancer cells could result from further increasing the cisplatin-elevated ROS levels by targeting antioxidant genes upregulated in cancers such as those mediated by the kinase Mirk/dyrk1B.